8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549



                                    FORM 8-K



                                 CURRENT REPORT

                       Pursuant to Section 13 or 15 (d) of
                       the Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): June 23, 2004


                          ENCYSIVE PHARMACEUTICALS INC.
             (Exact name of registrant as specified in its charter)



                                                    
        DELAWARE                     0-20117                          13-3532643
(State of Incorporation)     (Commission File Number)     (IRS Employer Identification No.)




                            6700 WEST LOOP, 4TH FLOOR
                              BELLAIRE, TEXAS 77401
              (Address of Registrant's principal executive offices)


                                 (713) 796-8822
              (Registrant's telephone number, including area code)


                                 Not Applicable
          (Former name or former address, if changed since last report)


ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

         On June 23, 2004, Encysive Pharmaceuticals Inc. (the "Company") issued
a press release announcing that J. Kevin Buchi, age 49, has been elected to the
Company's Board of Directors and appointed to serve on the Audit Committee. His
appointment brings to 11 the number of directors. Mr. Buchi has served as Senior
Vice President, Finance and Chief Financial Officer of Cephalon, Inc. since
April 1996, and previously held several financial positions with Cephalon,
including Controller, since joining the company in March 1991. Cephalon, a
Nasdaq-traded company, discovers, develops and markets innovative products to
treat neurological and sleep disorders, cancer and pain. He previously worked at
E. I. duPont de Nemours and Company, as a senior auditor at
PricewaterhouseCoopers and as a production chemist at Eastman Kodak Co. Mr.
Buchi is also a director of Lorus Therapeutics, a for-profit biotechnology
company. He is a graduate of Cornell University with a BA in Chemistry and a
minor in Economics, and holds an MBA from Kellogg Graduate School of Management
at Northwestern University. Mr. Buchi is also a Certified Public Accountant.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

         (c) Exhibits.

             99.1 Press Release.




                            [SIGNATURE PAGE FOLLOWS]


                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                  Encysive Pharmaceuticals Inc.

                                  By: /s/ Stephen L. Mueller
                                      ------------------------------------------
                                      Stephen L. Mueller
                                      Vice-President, Finance and Administration
Date: June 23, 2004                   Secretary and Treasurer


                                INDEX TO EXHIBITS


EXHIBIT NO.        DESCRIPTION
- -----------        -----------
   99.1            Press Release

EX-99.1

                                                                    EXHIBIT 99.1


Contact:

Media:                         Investors:
Daniel Budwick                 Ann Tanabe                        Hershel Berry
BMC Communications             Encysive Pharmaceuticals          The Trout Group
(212) 477-9007 ext. 14         (713) 796-8822                    (415) 392-3385


FOR IMMEDIATE RELEASE

     ENCYSIVE PHARMACEUTICALS APPOINTS J. KEVIN BUCHI TO BOARD OF DIRECTORS


HOUSTON, TX, JUNE 23, 2004 - Encysive Pharmaceuticals (NASDAQ:ENCY) today
announced that J. Kevin Buchi, 49, has been elected to the Company's Board of
Directors and appointed to serve on the Audit Committee. Mr. Buchi's appointment
brings to 11 the number of directors.

Mr. Buchi is Senior Vice President, Finance and Chief Financial Officer of
Cephalon, Inc. Mr. Buchi has helped guide Cephalon through several financings,
product and company acquisitions, and in the development and execution of
successful growth strategies. Prior to Cephalon, Mr. Buchi held positions at
E.I. duPont de Nemours and Company, PricewaterhouseCoopers, and Eastman Kodak
Co. Mr. Buchi holds a BA in Chemistry from Cornell University and an MBA from
Kellogg Graduate School of Management at Northwestern University. He is also a
Certified Public Accountant.

"Kevin's extensive experience and success in the biotechnology industry will be
invaluable as we move closer towards the commercialization of Thelin(TM), our
lead product candidate in Phase III development for pulmonary arterial
hypertension," said John M. Pietruski, Chairman of the Board of Encysive
Pharmaceuticals. "We are pleased to welcome Kevin to the Board and will look to
his expertise in the coming months and years."

ABOUT ENCYSIVE PHARMACEUTICALS

Encysive Pharmaceuticals Inc., a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs, is recognized for
our expertise in small molecule drug development and vascular biology.
Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline
for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III
development of the endothelin antagonist, Thelin, for pulmonary arterial
hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in
Phase II development with the selectin antagonist bimosiamose in asthma,
psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other
research and development programs ongoing for a range of cardiovascular and
inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit
our web site: www.encysive.com.

This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Among those risks, trends and
uncertainties are timing and cost of our clinical trials, attainment of


                                                                    EXHIBIT 99.1


research and clinical goals and milestones of product candidates, attainment of
required government approvals, sales levels of our products and availability of
financing, and revenues sufficient to fund development of product candidates and
operations. In particular, careful consideration should be given to cautionary
statements made in the various reports Encysive Pharmaceuticals, including as
Texas Biotechnology Corporation, has filed with the Securities and Exchange
Commission. The company undertakes no duty to update or revise these
forward-looking statements.

                                      # # #